Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Rapalog-Resistant Advanced PNET
NCT02893930Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 5 years. Started Apr 2017; status: completed.
02
Drugs
sapanisertib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02893930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893930.